%0 Journal Article
%T Key considerations in navigating ticagrelor's reported effect on heparin-induced thrombocytopenia functional assays in a landscape of limited data.
%A Salman G
%A Johannesmeyer HJ
%A Breen MJ
%J Am J Health Syst Pharm
%V 81
%N 12
%D 2024 Jun 11
%M 38365265
%F 2.98
%R 10.1093/ajhp/zxae040
%X <B>OBJECTIVE: </B>This article discusses key considerations regarding ticagrelor's reported effect on heparin-induced thrombocytopenia functional assays, such as literature gaps and possible management strategies.<BR><B>CONCLUSIONS: </B>Limited data indicate that ticagrelor may induce false-negative results in functional assays used in the diagnosis of heparin-induced thrombocytopenia. False-negative functional assays for heparin-induced thrombocytopenia could have catastrophic consequences. The manufacturer labeling of ticagrelor now includes a warning for this potential drug-laboratory interaction. This article suggests areas that would benefit from further research and strategies in navigating this possible interaction.<BR><B>CONCLUSIONS: </B>Clinicians should exercise caution when evaluating functional assays for heparin-induced thrombocytopenia in patients receiving ticagrelor. This article offers suggestions for future areas of research and potential management strategies.